Market Overview

UPDATE: Bank of America Downgrades Ariad Pharmaceuticals on Uncertain Iclusig Outlook

Share:
Related ARIA
10 Stocks Moving In Friday's Pre-Market Session
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors

In a report published Thursday, Bank of America analyst Rachel McMinn downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Buy to Neutral, and lowered the price target from $24.00 to $7.00.

In the report, Bank of America noted, “We rate ARIA a Neutral based on our view that uncertainties on the Iclusig safety profile will weaken near term adoption, limit visibility on timelines for future development, and limit overall market potential. ARIA's emerging second drug '113 potential is also uncertain given safety concerns and a competitive development environment.”

Ariad Pharmaceuticals closed on Wednesday at $5.83.

Latest Ratings for ARIA

DateFirmActionFromTo
Mar 2016JMP SecuritiesMaintainsMarket Outperform
Jan 2016BarclaysInitiates Coverage onUnderweight
Dec 2014Credit SuisseDowngradesNeutralUnderperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Bank of America Rachel McMinnAnalyst Color Downgrades Analyst Ratings

 

Related Articles (ARIA)

View Comments and Join the Discussion!